key: cord-0715388-xsky2q40
authors: Añón, José M.; Villar, Jesús
title: Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19
date: 2021-01-02
journal: Intensive Care Med
DOI: 10.1007/s00134-020-06330-w
sha: d91d8bd26f2494a57f2f31ec4cf34d61d4485155
doc_id: 715388
cord_uid: xsky2q40

nan

corticosteroid groups included dexamethasone at low and high doses, low-dose hydrocortisone, and high-dose methylprednisolone. The larger number of patients in the meta-analysis were those mechanically ventilated in the RECOVERY trial [2] (59.1% patients). Of note, the other trials also included patients who did not receive mechanical ventilation. Due to these and other limitations recognized by the authors, it is difficult to draw strong conclusions for COVID-19-related ARDS.

However, we postulate that the most important weakness of available evidence is that the primary outcome in the RECOVERY trial [2] and in the WHO REACT metaanalysis [3] was 28-day mortality. Assessing 28-day mortality may not be the optimal outcome in a trial. Since patients with severe COVID-19 often require prolonged intensive care unit (ICU) and hospital stays (beyond day-28), especially when receiving mechanical ventilation, it is unfortunate that long-term mortality (ICU, 60-day, or hospital mortality) was not reported in those two major studies. Recent data on corticosteroid therapy in the management of COVID-19 are also important, but far to represent a "milestone" precluding definitive conclusions. More studies are needed to evaluate issues such as type of corticosteroid, timing of initiation [5] , optimum dose, duration of treatment, and "mandatory" long-term mortality. Although the preliminary results of the RECOV-ERY trial [2] represented a gigantic optimism for this pandemic, it is time to know their final, long-term outcome data. Beneficial effects of 6 mg/day of dexamethasone at 28-day might not translate into longer-term benefit.

The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19

Dexamethasone in hospitalized patients with Covid-19-preliminary report

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Dexamethasone in ARDS network (2020) Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

COVADIS study group investigators (2020) Impact of late administration of corticosteroids in COVID-19 ARDS